Who needs laboratories and who needs statins? Comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines

Circulation: Cardiovascular Quality and Outcomes

Volumn 7, Issue 1, 2014, Pages 25-32

  Pandya, Ankur ^a   Weinstein, Milton C ^b   Salomon, Joshua A ^c   Cutler, D ^d   Gaziano, Thomas A ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Departments of Health Policy and Managemen   (United States)

^c Global Health and Population   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diagnosis; Economics; Primary prevention

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SCREENING; SENSITIVITY ANALYSIS;

DIAGNOSIS; ECONOMICS; PRIMARY PREVENTION;

ADULT; AGED; ALGORITHMS; CARDIOVASCULAR DISEASES; CLINICAL LABORATORY SERVICES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; NUTRITION SURVEYS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 84898724185     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000397     Document Type: Article

References (33)

1. Jackson R, Lynch J, Harper S. Preventing coronary heart disease. BMJ. 2006;332:617-618.
2. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, Ardal S, Alter DA, Laupacis A. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ. 2006;332:1419.
3. Mosca L. Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol. 2007;10(suppl 4):19-25.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(suppl 2):S1-S113.
5. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22:913-927.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
7. Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, Steyerberg EW, Hunink MG. Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med. 2010;170:27-40.
8. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet. 2008;371:923-931.
9. Pandya A, Weinstein MC, Gaziano TA. A comparative assessment of non-laboratory- based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One. 2011;6:e20416.
10. Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ. 2010;340:c1693.
11. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
12. Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Survey (2011). Hyattsville, MD: National Center for Health Statistics (NCHS); 2011.
13. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: Programs and collection procedures. Vital Health Stat 1. 1994:1-407.
14. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med. 2009;150:795-802.
15. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112:3569-3576.
16. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368:679-686.
17. Hunink MG, Glasziuo P, Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein MC. Decision Making in Health and Medicine. Cambridge, United Kingdom: Cambridge University Press; 2001.
18. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
19. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR, Anderson JL. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 2001;87:257-261.
20. Casalino LP, Dunham D, Chin MH, Bielang R, Kistner EO, Karrison TG, Ong MK, Sarkar U, McLaughlin MA, Meltzer DO. Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med. 2009;169:1123-1129.
21. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355:920-927.
22. Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011;342:d1672.
23. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243-254.
24. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146-153.
25. Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediateand low-cardiovascular-risk individuals for statin therapy. Circulation. 2010;122:1478-1487.
26. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2:65-72.
27. Owens DK. Improving practice guidelines with patient-specific recommendations. Ann Intern Med. 2011;154:638-639.
28. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in14 randomised trials of statins. Lancet. 2005;366:1267-1278.
29. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132:769-779.
30. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590.
31. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
32. Redberg RF, Katz MH. Healthy men should not take statins. JAMA. 2012;307:1491-1492.
33. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152:69-77.